Evaluating the VaLiANT (Valued Living After Neurological Trauma) group intervention for improving adjustment to life with acquired brain injury: A pilot randomized controlled trial

Abstract

There is a need for accessible rehabilitation that promotes meaningful participation, wellbeing, and adjustment to life with acquired brain injury (ABI). VaLiANT (Valued Living After Neurological Trauma) is an 8-week holistic group intervention that integrates Acceptance and Commitment Therapy (ACT) and cognitive rehabilitation techniques to support adjustment and meaningful reengagement in life. This Phase II pilot randomized controlled trial explored feasibility and preliminary efficacy signals to determine the viability of a larger trial. Adults (>3 months post-ABI) were randomly allocated to VaLiANT plus treatment-as-usual (TAU), or TAU waitlist-control, with assessments at baseline, post-intervention (8 weeks), and follow-up (16 weeks). Feasibility criteria included recruitment, dropout, outcome assessment completion, adherence, and delivery fidelity. Preliminary treatment effects were assessed on a range of adjustment-related outcomes using mixed linear models, proportions of reliable change, and minimal clinically important differences. 54 participants were recruited (Mage= 50.6, Myears-post-injury = 5.4) predominately with stroke (52%) and traumatic brain injury (22%). All feasibility criteria were met. Treatment effects were identified on measures of psychological distress, experiential avoidance, valued living, and self-identity, but not meaningful participation, quality-of-life, or wellbeing. A larger trial is viable but VaLiANT will benefit from refinement first to improve its impact on all intended outcomes. Trial registration: ACTRN12619001243101.